Efficacy Of PF-05089771 In Treating Postoperative Dental Pain

NCT01529346 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 235

Last updated 2018-06-01

Study results available
· View outcomes & findings →

Summary

The objective of this study is to evaluate the overall pain relief of a single dose of PF-05089771 against placebo following third molar extraction.

Conditions

  • Postoperative Dental Pain

Interventions

DRUG

PF-05089771

A single dose of PF-05089771 1600 mg oral solution administered once to the subject on Day 1 postoperatively

OTHER

Placebo

Placebo tablets for ibuprofen: 2 X 200 mg placebo tablets administered orally once to the subject on Day 1 postoperatively

DRUG

PF-05089771

A single dose of PF-05089771 450 mg oral solution administered once to the subject on Day 1 postoperatively

OTHER

Placebo

Placebo tablets for ibuprofen: 2 X 200 mg placebo tablets administered orally once to the subject on Day 1 postoperatively

DRUG

PF-05089771

A single dose of PF-05089771 150 mg oral solution administered once to the subject on Day 1 postoperatively

OTHER

Placebo

Placebo tablets for ibuprofen: 2 X 200 mg placebo tablets administered orally once to the subject on Day 1 postoperatively

DRUG

Ibuprofen

2 X 200 mg tablets of ibuprofen administered orally once to the subject on Day 1 postoperatively

OTHER

Placebo

Placebo solution for PF-05089771: A single dose of Placebo solution administered once to the subject on Day 1 postoperatively

OTHER

Placebo

Placebo solution for PF-05089771:A single dose of Placebo solution administered once to the subject on Day 1 postoperatively

OTHER

Placebo

Placebo tablets for Ibuprofen: 2 X 200 mg placebo tablets administered orally once to the subject on Day 1 postoperatively

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-12-12
Primary Completion
2012-06-25
Completion
2012-06-25

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01529346 on ClinicalTrials.gov